制度创新理论视角下我国药品研发制度变迁设计  

Institutional Change Design of Drug Research and Development in China from the Perspective of Institutional Innovation Theory

作　　者：毛心仪 姚峥嵘 MAOXin-yi;YAOZheng-rong(School of Health Economics and Management,Nanjing University of Traditional Chinese Medicine,Nanjing Jiangsu 210023,China;不详)

机构地区：[1]南京中医药大学卫生经济管理学院,江苏南京210023

出　　处：《卫生经济研究》2021年第7期38-43,共6页

基　　金：教育部人文社会科学研究规划基金项目(16YJA820022)。

摘　　要：药品研发是保证新药可及性和药品质量的关键。本文基于制度创新理论,总结药品研发的投入产出情况,针对药品研发外部激励制度不均衡和内部治理制度不均衡问题,提出强制性制度变迁和诱致性制度变迁的设计建议,促进药品研发制度达到均衡状态。Drug research and development are the key to ensure accessibility and quality of new drugs.Based on the theory of institutional innovation,this paper summarizes the input and output of drug research and development,and aiming at the imbalance of external incentive system and internal governance system of drug research and development,puts forward the design suggestions of compulsory institutional change and induced institutional change to promote the equilibrium state of drug research and development system.

关 键 词：药品研发 制度创新理论 制度变迁 

分 类 号：R19[医药卫生—卫生事业管理]